These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 22420940)

  • 1. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
    Sasso O; Bertorelli R; Bandiera T; Scarpelli R; Colombano G; Armirotti A; Moreno-Sanz G; Reggiani A; Piomelli D
    Pharmacol Res; 2012 May; 65(5):553-63. PubMed ID: 22420940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
    Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
    Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
    Slivicki RA; Xu Z; Mali SS; Hohmann AG
    Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
    Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
    J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.
    Naidu PS; Booker L; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2009 Apr; 329(1):48-56. PubMed ID: 19118134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
    Nasirinezhad F; Jergova S; Pearson JP; Sagen J
    Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive.
    Sasso O; Wagner K; Morisseau C; Inceoglu B; Hammock BD; Piomelli D
    Pharmacol Res; 2015 Jul; 97():7-15. PubMed ID: 25882247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier.
    Moreno-Sanz G; Sasso O; Guijarro A; Oluyemi O; Bertorelli R; Reggiani A; Piomelli D
    Br J Pharmacol; 2012 Dec; 167(8):1620-8. PubMed ID: 22774772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
    Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C
    Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
    Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
    J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine.
    Greco R; Demartini C; Zanaboni A; Casini I; De Icco R; Reggiani A; Misto A; Piomelli D; Tassorelli C
    Neurobiol Dis; 2021 Jan; 147():105157. PubMed ID: 33129939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of peripheral FAAH blockade on NTG-induced hyperalgesia--evaluation of URB937 in an animal model of migraine.
    Greco R; Bandiera T; Mangione AS; Demartini C; Siani F; Nappi G; Sandrini G; Guijarro A; Armirotti A; Piomelli D; Tassorelli C
    Cephalalgia; 2015 Oct; 35(12):1065-76. PubMed ID: 25608877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats.
    Vozella V; Ahmed F; Choobchian P; Merrill CB; Zibardi C; Tarzia G; Mor M; Duranti A; Tontini A; Rivara S; Piomelli D
    J Pharm Pharmacol; 2019 Dec; 71(12):1762-1773. PubMed ID: 31579946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antinociceptive effects of concomitant NAAA and peripheral FAAH inhibition.
    Mabou Tagne A; Fotio Y; Uppal PS; Piomelli D
    Exp Neurol; 2022 Nov; 357():114194. PubMed ID: 35932800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.
    Anderson WB; Gould MJ; Torres RD; Mitchell VA; Vaughan CW
    Neuropharmacology; 2014 Jun; 81():224-30. PubMed ID: 24384256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
    Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.
    Kinsey SG; Naidu PS; Cravatt BF; Dudley DT; Lichtman AH
    Pharmacol Biochem Behav; 2011 Oct; 99(4):718-25. PubMed ID: 21740924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain.
    Ahn K; Smith SE; Liimatta MB; Beidler D; Sadagopan N; Dudley DT; Young T; Wren P; Zhang Y; Swaney S; Van Becelaere K; Blankman JL; Nomura DK; Bhattachar SN; Stiff C; Nomanbhoy TK; Weerapana E; Johnson DS; Cravatt BF
    J Pharmacol Exp Ther; 2011 Jul; 338(1):114-24. PubMed ID: 21505060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
    Sasso O; Moreno-Sanz G; Martucci C; Realini N; Dionisi M; Mengatto L; Duranti A; Tarozzo G; Tarzia G; Mor M; Bertorelli R; Reggiani A; Piomelli D
    Pain; 2013 Mar; 154(3):350-360. PubMed ID: 23218523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors.
    Holt S; Comelli F; Costa B; Fowler CJ
    Br J Pharmacol; 2005 Oct; 146(3):467-76. PubMed ID: 16100529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.